ABSTRACT
This study aims to analyze the reversal of lipopolysaccharide (LPS)-induced cardiomyocyte apoptosis via α7nAChR by dexmedetomidine (Dex), so as to provide references for clinical treatment of myocardial disorders in the future. First, the research team divided cardiomyocytes (H9C2) were divided into a control group (normal culture), an LPS group (LPS-induced injury model), and an experimental group (pretreated with Dex before LPS induction). Subsequently, lactate dehydrogenase (LDH) and cell activity were detected, and the research team found that the LDH content of the control, experimental and LPS groups were in ascending order (P<0.05). The cell viability decreased and apoptosis increased in the LPS group, with cells mainly concentrating in the G2-M phase; the viability increased and apoptosis decreased in the experimental group, with blocked G1-G0 phase (P<0.05). This demonstrates that Dex can reverse LPS-induced apoptosis in cardiomyocytes. Subsequently, the research group also detected the expression of α7nAChR and NF-κB/AKT pathway, and it was seen that the expression of α7nAChR in the LPS group was higher than that in the control group, with activated NF-κB/AKT pathway; the α7nAChR expression in the experimental group was further elevated, but the NF-κB/AKT pathway was inhibited (P<0.05). The effects of Dex on cardiomyocytes were seen to be related to the α7nAChR and NF-κB/AKT pathways.
Subject(s)
Apoptosis , Cell Survival , Dexmedetomidine , Lipopolysaccharides , Myocytes, Cardiac , NF-kappa B , Proto-Oncogene Proteins c-akt , Signal Transduction , alpha7 Nicotinic Acetylcholine Receptor , Dexmedetomidine/pharmacology , Myocytes, Cardiac/drug effects , Myocytes, Cardiac/metabolism , Apoptosis/drug effects , Lipopolysaccharides/pharmacology , alpha7 Nicotinic Acetylcholine Receptor/metabolism , Rats , Animals , Proto-Oncogene Proteins c-akt/metabolism , NF-kappa B/metabolism , Signal Transduction/drug effects , Cell Survival/drug effects , Cell Line , L-Lactate Dehydrogenase/metabolismABSTRACT
ABSTRACT: Cardiopulmonary bypass (CPB) is very commonly performed among the cardiovascular surgeries, and delayed recovery (DR) is a kind of serious complications in patients with CPB. It is necessary to assess the risk factors for DR in patients with CPB, to provide evidence into the management of CPB patients.Patients undergoing CPB in our hospital from January 2018 to March 2020 were included. Cases that consciousness has not recovered 12âhours after anesthesia were considered as DR. The preoperative and intraoperative variables of CPB patients were collected and analyzed. Logistic regressions were conducted to analyze the potential influencing factor.A total of 756 CPB patients were included, and the incidence of DR was 9.79%. There were significant differences on the age, aspartate aminotransferase (AST), glutamic pvruvic transaminase (ALT), blood urea nitrogen (BUN), and serum creatinine (SCr) between patients with and without DR (all Pâ<â.05); there were no significant differences in the types of surgical procedure (all Pâ>â.05); there were significant differences on the duration of CPB, duration of aortic cross clamp (ACC), duration of surgery, minimum nasopharyngeal temperature, and transfusion of packed red blood cells between patients with and without DR (all Pâ<â.05). Logistic regression analysis indicated that duration of CPB ≥132âminutes (odds ratio [OR] 4.12, 1.02-8.33), BUN ≥9âmmol/L (OR 4.05, 1.37-8.41), infusion of red blood cell suspension (OR 3.93, 1.25-7.63), duration of surgery ≥350âminutes (OR 3.17, 1.24-5.20), age ≥6 (OR 3.01, 1.38-6.84) were the independent risk factors for DR in patients with CPB (all Pâ<â.05).Extra attention and care are needed for those CPB patients with duration of CPB ≥132âminutes, BUN ≥9âmmol/L, infusion of red blood cell suspension, duration of surgery ≥350âminutes, and age ≥60.